130 related articles for article (PubMed ID: 37590967)
1. Performance of DNA-based biomarkers for classification of adrenocortical carcinoma: a prognostic study.
Lippert J; Dischinger U; Appenzeller S; Prete A; Kircher S; Skordilis K; Elhassan YS; Altieri B; Fassnacht M; Ronchi CL
Eur J Endocrinol; 2023 Aug; 189(2):262-270. PubMed ID: 37590967
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Targeted Methylation Analysis in Paraffin-embedded Samples of Adrenocortical Carcinoma.
Lippert J; Altieri B; Morrison B; Steinhauer S; Smith G; Lorey A; Urlaub H; Kircher S; Sitch A; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2022 Sep; 107(10):2892-2899. PubMed ID: 35929659
[TBL] [Abstract][Full Text] [Related]
3. Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication.
Lippert J; Appenzeller S; Liang R; Sbiera S; Kircher S; Altieri B; Nanda I; Weigand I; Gehrig A; Steinhauer S; Riemens RJM; Rosenwald A; Müller CR; Kroiss M; Rost S; Fassnacht M; Ronchi CL
J Clin Endocrinol Metab; 2018 Dec; 103(12):4511-4523. PubMed ID: 30113656
[TBL] [Abstract][Full Text] [Related]
4. S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study.
Elhassan YS; Altieri B; Berhane S; Cosentini D; Calabrese A; Haissaguerre M; Kastelan D; Fragoso MCBV; Bertherat J; Al Ghuzlan A; Haak H; Boudina M; Canu L; Loli P; Sherlock M; Kimpel O; Laganà M; Sitch AJ; Kroiss M; Arlt W; Terzolo M; Berruti A; Deeks JJ; Libé R; Fassnacht M; Ronchi CL
Eur J Endocrinol; 2021 Nov; 186(1):25-36. PubMed ID: 34709200
[TBL] [Abstract][Full Text] [Related]
5. DNA Methylation Is an Independent Prognostic Marker of Survival in Adrenocortical Cancer.
Jouinot A; Assie G; Libe R; Fassnacht M; Papathomas T; Barreau O; de la Villeon B; Faillot S; Hamzaoui N; Neou M; Perlemoine K; Rene-Corail F; Rodriguez S; Sibony M; Tissier F; Dousset B; Sbiera S; Ronchi C; Kroiss M; Korpershoek E; de Krijger R; Waldmann J; K D; Bartsch ; Quinkler M; Haissaguerre M; Tabarin A; Chabre O; Sturm N; Luconi M; Mantero F; Mannelli M; Cohen R; Kerlan V; Touraine P; Barrande G; Groussin L; Bertagna X; Baudin E; Amar L; Beuschlein F; Clauser E; Coste J; Bertherat J
J Clin Endocrinol Metab; 2017 Mar; 102(3):923-932. PubMed ID: 27967600
[TBL] [Abstract][Full Text] [Related]
6. Cumulative GRAS Score as a Predictor of Survival After Resection for Adrenocortical Carcinoma: Analysis From the U.S. Adrenocortical Carcinoma Database.
Baechle JJ; Marincola Smith P; Solórzano CC; Tran TB; Postlewait LM; Maithel SK; Prescott J; Pawlik T; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Shirley LA; Fields RC; Jin L; Abbott DE; Ronnekleiv-Kelly S; Sicklick JK; Yopp A; Mansour J; Duh QY; Seiser N; Votanopoulos K; Levine EA; Poultsides G; Kiernan CM
Ann Surg Oncol; 2021 Oct; 28(11):6551-6561. PubMed ID: 33586069
[TBL] [Abstract][Full Text] [Related]
7. Contrast CT radiomic features add value to prediction of prognosis in adrenal cortical carcinoma.
Liu J; Lin W; Yan L; Xie J; Dai J; Xu D; Zhao J
Endocrine; 2024 Mar; 83(3):763-774. PubMed ID: 37968537
[TBL] [Abstract][Full Text] [Related]
8. Circulating cell-free DNA-based biomarkers for prognostication and disease monitoring in adrenocortical carcinoma.
Lippert J; Smith G; Appenzeller S; Landwehr LS; Prete A; Steinhauer S; Asia M; Urlaub H; Elhassan YS; Kircher S; Arlt W; Fassnacht M; Altieri B; Ronchi CL
Eur J Endocrinol; 2024 Mar; 190(3):234-247. PubMed ID: 38451242
[TBL] [Abstract][Full Text] [Related]
9. Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.
Liang J; Liu Z; Wei X; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Lu Y; Zhu Y
BMC Cancer; 2019 Nov; 19(1):1165. PubMed ID: 31783819
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study.
Libé R; Borget I; Ronchi CL; Zaggia B; Kroiss M; Kerkhofs T; Bertherat J; Volante M; Quinkler M; Chabre O; Bala M; Tabarin A; Beuschlein F; Vezzosi D; Deutschbein T; Borson-Chazot F; Hermsen I; Stell A; Fottner C; Leboulleux S; Hahner S; Mannelli M; Berruti A; Haak H; Terzolo M; Fassnacht M; Baudin E;
Ann Oncol; 2015 Oct; 26(10):2119-25. PubMed ID: 26392430
[TBL] [Abstract][Full Text] [Related]
11. The clinical utility of 'GRAS' parameters in stage I-III adrenocortical carcinomas: long-term data from a high-volume institution.
Liang J; Liu Z; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Wei X; Lu Y; Zhu Y
Endocrine; 2020 Feb; 67(2):449-456. PubMed ID: 31786772
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma.
Liang J; Liu Z; Pei T; Xiao Y; Zhou L; Tang Y; Zhou C; Wu K; Zhang F; Zhang F; Yin X; Chen N; Wei X; Lu Y; Zhu Y
Dis Markers; 2020; 2020():5354825. PubMed ID: 31998416
[TBL] [Abstract][Full Text] [Related]
13. Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma.
Jouinot A; Lippert J; Sibony M; Violon F; Jeanpierre L; De Murat D; Armignacco R; Septier A; Perlemoine K; Letourneur F; Izac B; Ragazzon B; Leroy K; Pasmant E; North MO; Gaujoux S; Dousset B; Groussin L; Libe R; Terris B; Fassnacht M; Ronchi CL; Bertherat J; Assie G
Eur J Endocrinol; 2022 Apr; 186(6):607-617. PubMed ID: 35266879
[TBL] [Abstract][Full Text] [Related]
14. Role of FGF Receptors and Their Pathways in Adrenocortical Tumors and Possible Therapeutic Implications.
Sbiera I; Kircher S; Altieri B; Lenz K; Hantel C; Fassnacht M; Sbiera S; Kroiss M
Front Endocrinol (Lausanne); 2021; 12():795116. PubMed ID: 34956100
[TBL] [Abstract][Full Text] [Related]
15. Assessment of prognostic factors in pediatric adrenocortical tumors: a systematic review and evaluation of a modified S-GRAS score.
Riedmeier M; Decarolis B; Haubitz I; Reibetanz J; Wiegering A; Härtel C; Schlegel PG; Fassnacht M; Wiegering V
Eur J Endocrinol; 2022 Dec; 187(6):751-763. PubMed ID: 36193775
[TBL] [Abstract][Full Text] [Related]
16. Targeted Assessment of
Mohan DR; Lerario AM; Else T; Mukherjee B; Almeida MQ; Vinco M; Rege J; Mariani BMP; Zerbini MCN; Mendonca BB; Latronico AC; Marie SKN; Rainey WE; Giordano TJ; Fragoso MCBV; Hammer GD
Clin Cancer Res; 2019 Jun; 25(11):3276-3288. PubMed ID: 30770352
[TBL] [Abstract][Full Text] [Related]
17. Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
Weigand I; Altieri B; Lacombe AMF; Basile V; Kircher S; Landwehr LS; Schreiner J; Zerbini MCN; Ronchi CL; Megerle F; Berruti A; Canu L; Volante M; Paiva I; Della Casa S; Sbiera S; Fassnacht M; Fragoso MCBV; Terzolo M; Kroiss M
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32449514
[TBL] [Abstract][Full Text] [Related]
18. Screening for Prognostic Biomarkers in Metastatic Adrenocortical Carcinoma by Tissue Micro Arrays Analysis Identifies P53 as an Independent Prognostic Marker of Overall Survival.
Hescot S; Faron M; Kordahi M; Do Cao C; Naman A; Lamartina L; Hadoux J; Leboulleux S; Pattou F; Aubert S; Scoazec JY; Al Ghuzlan A; Baudin E
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565353
[TBL] [Abstract][Full Text] [Related]
19. Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma.
Assié G; Jouinot A; Fassnacht M; Libé R; Garinet S; Jacob L; Hamzaoui N; Neou M; Sakat J; de La Villéon B; Perlemoine K; Ragazzon B; Sibony M; Tissier F; Gaujoux S; Dousset B; Sbiera S; Ronchi CL; Kroiss M; Korpershoek E; De Krijger R; Waldmann J; Quinkler M; Haissaguerre M; Tabarin A; Chabre O; Luconi M; Mannelli M; Groussin L; Bertagna X; Baudin E; Amar L; Coste J; Beuschlein F; Bertherat J
JAMA Oncol; 2019 Oct; 5(10):1440-1447. PubMed ID: 31294750
[TBL] [Abstract][Full Text] [Related]
20. Prognosis and Therapeutic Efficacy Prediction of Adrenocortical Carcinoma Based on a Necroptosis-Associated Gene Signature.
Ji D; Zhong R; Fan S
Biomed Res Int; 2022; 2022():8740408. PubMed ID: 35647181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
